{
  "source": "PA-Med-Nec-Tarpeyo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2268-6\nProgram Prior Authorization/Medical Necessity\nMedication Tarpeyo® (budesonide delayed-release capsules)\nP&T Approval Date 2/2022, 4/2022, 7/2022, 7/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nTarpeyo (budesonide delayed-release capsule) is indicated to reduce the loss of kidney function\nin adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease\nprogression.\n2. Coverage Criteriaa:\nA. Authorization\n1. Tarpeyo will be approved based on all of the following:\na. Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal\nbiopsy\n-AND-\nb. Patient is at risk for disease progression\n-AND-\nc. Used to reduce the loss of kidney function\n-AND-\nd. Estimated glomerular filtration rate (eGFR) ≥ 35 mL/min/1.73 m2\n-AND-\ne. One of the following:\n1) Patient is on a stabilized dose and receiving concomitant therapy with one of the\nfollowing:\na) maximally tolerated angiotensin converting enzyme (ACE) inhibitor (e.g.\ncaptopril, enalapril)\nb) maximally tolerated angiotensin II receptor blocker (ARB) (e.g. candesartan,\nvalsartan)\n-OR-\n© 2025 UnitedHealthcare Services Inc.\n1\n2) Patient has an allergy, contraindication, or intolerance to ACE inhibitors and\nARB\n-AND-\nf. History of failure, contraindication or intolerance to a 30-day trial of a glucocorticoid\n(e.g., methylprednisolone, prednisone)\n-AND-\ng. Prescribed by or in consultation with a nephrologist\nAuthorization will be issued for 9 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-app",
    "Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic\nclass.\n• Supply limits may be in place.\n4. References:\n1. Tarpeyo [package insert]. Stockholm, Sweden: Calliditas Therapeutics AB; June 2024\n2. KDIGO 2021 Glomerular Diseases Guideline. October 2021; 100 (4S).\nProgram Prior Authorization/Medical Necessity – Tarpeyo\nChange Control\nDate Change\n2/2022 New program\n4/2022 Removed Immunologist prescriber requirement and updated urine\nprotein-to-creatinine ratio (UPCR) of ≥ 1.5 g/g to be an example along\nwith the International IgAN Prediction Tool.\n7/2022 Added requirement of IgAN confirmed by renal biopsy and a 30-day\ntrial of a glucocorticoid.\n7/2023 Annual review. No changes.\n2/2024 Updated indication and removed example for disease progression.\nUpdated references.\n2/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}